---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002839"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:08:03.868069+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Carisma updates pipeline: CT-1119 Phase 1 start H1 2025, liver fibrosis IND in 2026

## Summary
- CT-1119 (mesothelin-targeted CAR-Monocyte) Phase 1 trial with tislelizumab in solid tumors expected to start H1 2025.
- Phase 1 trial to enroll up to 12 patients in China; initial safety/efficacy data anticipated Q4 2025.
- Liver fibrosis program: preclinical in 2025 to enable regulatory submission in 2026, followed by Phase 1 in 2026.
- Corporate presentation updated on company website with these pipeline milestones.

## SEC filing metadata
- accession: 0001104659-25-002839
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465925002839/0001104659-25-002839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465925002839/tm253058d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002839
- JSON: https://secwatch.observer/filing/0001104659-25-002839.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.